Micro Market Monitor: Asia-Pacific Clinical Chemistry Market
DUBLIN, Dec. 18, 2014 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/8s36gz/micro_market) has announced the addition of the "Micro Market Monitor: Asia-Pacific Clinical Chemistry Market" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
The Asia-Pacific clinical chemistry market is growing due to the ongoing developments in analytical laboratory automation, the swift progress in various fields of diagnosis such as point-of-care testing, molecular diagnosis, immunoassays, hematology, flow cytometry, and microbiology, and finally, the geographical market expansion within emerging countries. The market in this region is growing in double digits and will continue to grow in future. China commanded the largest share (53%) at an estimated $516.81 million in 2013 and is expected to reach $1,047.2 million by 2018, at a CAGR of 16% from 2013 to 2018.
The most important trend witnessed recently in the in vitro diagnostics (IVD) industry is the trend of self-testing as opposed to patients visiting hospitals. This is one of the biggest factors responsible for the growth of point-of-care testing, as patients prefer self-testing so as to avoid unnecessary visits to the hospital. Clinical chemistry accounted for 21.3% share of the IVD market in 2012. Clinical chemistry routine tests such as testing for blood albumin, ALT/SGPT, ammonia, blood gases, and calcium and creatinine levels, are required before undergoing advanced tests. These tests, thus, form the center stage of the IVD market. The United States commanded the largest share (89%) of the North American clinical chemistry market at an estimated $3,852.7 million in 2013 and is expected to reach $5,370.5 million by 2019, at a CAGR of 7.2% from 2013 to 2018.
The major changes in clinical chemistry have been brought about as a result of the convergence of system engineering, automation, and IT technology. Thus, new technologies have enabled a better understanding of disease processes. The clinical chemistry market is expanding, consolidating, and becoming highly competitive with a myriad of opportunities for various new instruments, reagents, calibrators, and other systems.
The Center for Medicare & Medicaid Services (CMS) has estimated that healthcare spending in the U.S. is expected to grow from $2.7 trillion in 2011 to about $4.6 trillion in 2019, at a CAGR of 6.8% for the same period. Similarly, in emerging countries, the growing awareness and an increasing middle-class population, with a more disposable income to spend on healthcare, will be the major driving factors for the growth of this market.
The report on the Asia-Pacific clinical chemistry market analyzes the market by three segments, namely, clinical chemistry reagents, instruments, and accessories. The report also provides an extensive competitive landscaping of companies operating in this market. The main companies extensively covered in this report are Abbott Laboratories, Alere, Inc., Arkray, Inc., Bayer AG, Becton, Dickinson and Company, bioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, Diagnostica Stago S.A.S, DiaSorin S.p.A., Hologic, Inc., Horiba, Johnson & Johnson, Novartis International AG, Qiagen N.V., Roche Diagnostics, Siemens Healthcare, Sysmex Corporation, Thermo Fisher Scientific, Inc., and others.
Key Topics Covered:
1 Introduction
2 Executive Summary
3 Market Overview
Companies Mentioned:
- Abbott Diagnostics Inc.
- Beckman Coulter Inc. (Subsidiary Of Danaher Corporation)
- Fujifilm Holdings Corporation
- Hitachi Ltd
- Horiba Ltd
- Mindray Medical International Limited
- Orthoclinical Diagnostics
- Randox Laboratories
- Roche Diagnostics Limited
- Siemens Healthcare
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Toshiba Corporation
- Transasia Bio-Medicals Ltd.
For more information visit http://www.researchandmarkets.com/research/8s36gz/micro_market
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article